

Microbiota-based therapies for liver disease



Bernd Schnabl, M.D., FAASLD, AGAF

Professor of Medicine

Division of Gastroenterology

University of California San Diego

JOIN VIA ZOOM



About this seminar: Our research focus is to understand the complex multi-directional interactions that occur between the gut microbiota and the liver. We pioneered the characterization of the intestinal bacterial microbiota, mycobiome and virome in patients with liver disease. We use microbiota centered therapies such as phages and synthetic bacteria to treat liver disease.

References:

1. Yang A, Schnabl B, et al. **Intestinal fungi contribute to development of alcoholic liver disease.** J Clin Invest. 2017; 127(7):2829-2841. PMCID: PMC5490775.
2. Duan Y, Schnabl B, et al. **Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.** Nature. 2019, 575(7783):505-511. PMCID: PMC6872939.
3. Lang S, Schnabl B, et al. **Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.** Gastroenterology. 2020; 159(5):1839-1852. PMID: 32652145.

SEPT. 30 • 4:00 PM

<https://tinyurl.com/y5rd2uut>

Meeting ID: 951 0349 9512
Password: 2020



For more info:
escamill@bcm.edu
(713) 798-3478